CO6821892A2 - Anticuerpos anti-angptl3 y usos de los mismos - Google Patents

Anticuerpos anti-angptl3 y usos de los mismos

Info

Publication number: CO6821892A2
Authority: CO; Colombia
Prior art keywords: angptl3 antibodies; angptl3; antibodies
Prior art date: 2011-06-17

Application number

CO13292222A

Other languages

English (en)

Inventor

Mark W Sleeman

Murphy Gusarova

Andrew Murphy

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-17

Filing date

2013-12-13

Publication date

2013-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6821892(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-13 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2013-12-31 Publication of CO6821892A2 publication Critical patent/CO6821892A2/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CO13292222A 2011-06-17 2013-12-13 Anticuerpos anti-angptl3 y usos de los mismos CO6821892A2 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161498518P	2011-06-17	2011-06-17
US201161578309P	2011-12-21	2011-12-21

Publications (1)

Publication Number	Publication Date
CO6821892A2 true CO6821892A2 (es)	2013-12-31

Family

ID=46298728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CO13292222A CO6821892A2 (es)	2011-06-17	2013-12-13	Anticuerpos anti-angptl3 y usos de los mismos

Country Status (44)

Country	Link
US (6)	US9018356B2 (es)
EP (2)	EP3418301A1 (es)
JP (2)	JP6400471B2 (es)
KR (1)	KR102031007B1 (es)
CN (1)	CN103732624B (es)
AR (1)	AR087329A1 (es)
AU (1)	AU2012271663B2 (es)
CA (1)	CA2838867C (es)
CL (1)	CL2013003552A1 (es)
CO (1)	CO6821892A2 (es)
CR (1)	CR20130621A (es)
CY (2)	CY1120996T1 (es)
DK (1)	DK2721065T3 (es)
DO (1)	DOP2013000299A (es)
EC (1)	ECSP13013085A (es)
ES (1)	ES2699499T3 (es)
FI (1)	FIC20210028I1 (es)
GT (1)	GT201300306A (es)
HR (1)	HRP20182098T1 (es)
HU (1)	HUS2100034I1 (es)
IL (2)	IL229612B (es)
JO (1)	JO3412B1 (es)
LT (2)	LT2721065T (es)
LU (1)	LUC00231I2 (es)
MA (1)	MA35190B1 (es)
MX (2)	MX337644B (es)
MY (1)	MY160516A (es)
NI (1)	NI201300136A (es)
NL (1)	NL301122I2 (es)
NO (1)	NO2021037I1 (es)
PE (1)	PE20141166A1 (es)
PL (1)	PL2721065T3 (es)
PT (1)	PT2721065T (es)
RS (1)	RS58310B1 (es)
RU (1)	RU2620064C2 (es)
SG (1)	SG195165A1 (es)
SI (1)	SI2721065T1 (es)
SM (1)	SMT201800658T1 (es)
TR (1)	TR201816591T4 (es)
TW (3)	TWI644922B (es)
UA (1)	UA114891C2 (es)
UY (2)	UY39340A (es)
WO (1)	WO2012174178A1 (es)
ZA (1)	ZA201308879B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR087329A1 (es) *	2011-06-17	2014-03-19	Regeneron Pharma	Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US9255154B2 (en)	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
AR095196A1 (es)	2013-03-15	2015-09-30	Regeneron Pharma	Medio de cultivo celular libre de suero
WO2017011929A1 (zh) *	2015-07-17	2017-01-26	北京大学第一医院	检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TWI797060B (zh)	2015-08-04	2023-04-01	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
TW201713690A (zh)	2015-08-07	2017-04-16	再生元醫藥公司	抗ａｎｇｐｔｌ８抗體及其用途
MX2018009680A (es) *	2016-02-17	2018-09-10	Regeneron Pharma	Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3.
EP3423157A1 (en) *	2016-03-03	2019-01-09	Regeneron Pharmaceuticals, Inc.	Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
LT3439689T (lt) *	2016-04-08	2021-11-10	Regeneron Pharmaceuticals, Inc.	Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi
KR20220148299A (ko) *	2016-04-28	2022-11-04	리제너론 파아마슈티컬스, 인크.	가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법
EP3504328A1 (en)	2016-08-24	2019-07-03	Regeneron Pharmaceuticals, Inc.	Host cell protein modification
CA3044249A1 (en)	2016-11-17	2018-05-24	Regeneron Pharmaceuticals, Inc.	Methods of treating obesity with anti-angptl8 antibodies
KR102659791B1 (ko)	2017-07-06	2024-04-23	리제너론 파마슈티칼스 인코포레이티드	당단백질을 만들기 위한 세포 배양 과정
WO2019126194A1 (en)	2017-12-18	2019-06-27	Regeneron Pharmaceuticals, Inc.	Angptl8 assay and uses thereof
AU2018392334A1 (en)	2017-12-22	2020-05-28	Regeneron Pharmaceuticals, Inc.	System and method for characterizing drug product impurities
JP7349998B2 (ja)	2018-01-31	2023-09-25	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法
TW202311746A (zh)	2018-02-02	2023-03-16	美商再生元醫藥公司	用於表徵蛋白質二聚合之系統及方法
JP2021514609A (ja)	2018-02-28	2021-06-17	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	ウイルス混入物質を同定するためのシステムおよび方法
EP3768709B1 (en)	2018-03-19	2023-12-27	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
TW202016125A (zh)	2018-05-10	2020-05-01	美商再生元醫藥公司	用於定量及調節蛋白質黏度之系統與方法
MX2021002279A (es)	2018-08-27	2021-05-27	Regeneron Pharma	Uso de espectroscopia raman en la purificacion corriente abajo.
US11754569B2 (en)	2018-08-30	2023-09-12	Regeneron Pharmaceuticals, Inc.	Methods for characterizing protein complexes
WO2020109978A1 (en) *	2018-11-26	2020-06-04	Novartis Ag	Lpl-gpihbp1 fusion polypeptides
TWI747098B (zh)	2018-12-21	2021-11-21	美商美國禮來大藥廠	抗angptl3/8複合物抗體及其使用方法
FI3857237T3 (fi)	2019-01-16	2023-05-03	Regeneron Pharma	Disulfidisidosten luonnehtimismenetelmiä
WO2020185952A1 (en) *	2019-03-11	2020-09-17	xCella Biosciences, Inc.	Cd27-binding antibodies and uses thereof
SG11202110911RA (en)	2019-05-13	2021-10-28	Regeneron Pharma	Improved competitive ligand binding assays
US20200369760A1 (en) *	2019-05-24	2020-11-26	Regeneron Pharmaceuticals, Inc.	Stabilized formulations containing anti-angptl3 antibodies
CN112062844B (zh) *	2019-06-10	2022-07-19	山东博安生物技术股份有限公司	抗angptl3抗体及其用途
WO2021001804A1 (en) *	2019-07-04	2021-01-07	Cadila Healthcare Limited	Angptl3 based vaccine for the treatment of liver disease
EP4034870A1 (en)	2019-09-24	2022-08-03	Regeneron Pharmaceuticals, Inc.	Systems and methods for chromatography use and regeneration
EP4065086A1 (en)	2019-11-25	2022-10-05	Regeneron Pharmaceuticals, Inc.	Sustained release formulations using non-aqueous emulsions
CN110938144B (zh) *	2019-11-27	2022-07-26	复旦大学附属儿科医院	一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
CA3165060C (en)	2020-01-21	2023-06-20	Yiming Zhao	Deglycosylation methods for electrophoresis of glycosylated proteins
CA3166346A1 (en) *	2020-01-22	2021-07-29	Jiangsu Hengrui Medicine Co., Ltd.	Anti-angptl3 antibody and use thereof
TW202225398A (zh)	2020-08-31	2022-07-01	美商再生元醫藥公司	用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略
CA3191141A1 (en)	2020-11-25	2022-06-02	Hunter Chen	Sustained release formulations using non-aqueous membrane emulsification
US20220257707A1 (en)	2020-12-17	2022-08-18	Regeneron Pharmaceuticals, Inc.	Fabrication of protein-encapsulating microgels
JP2024503408A (ja)	2021-01-20	2024-01-25	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	細胞培養におけるタンパク質力価の改善方法
AR125585A1 (es)	2021-03-03	2023-08-02	Regeneron Pharma	Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
US20240141029A1 (en) *	2021-03-05	2024-05-02	Anji Pharmaceuticals Inc.	Methods and compositions for treating sepsis
MX2023010794A (es)	2021-03-26	2023-10-25	Regeneron Pharma	Metodos y sistemas para el desarrollo de protocolos de mezcla.
WO2022205021A1 (zh) *	2021-03-30	2022-10-06	复旦大学附属儿科医院	一种抗angptl3抗体或其抗原结合片段及其制备方法和用途
AU2022286340A1 (en)	2021-06-01	2024-01-04	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
JP2024529377A (ja) *	2021-07-21	2024-08-06	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	抗ａｎｇｐｔｌ３抗体又はその抗原結合断片の医薬組成物及びその使用
WO2023039457A1 (en)	2021-09-08	2023-03-16	Regeneron Pharmaceuticals, Inc.	A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
US20230090912A1 (en)	2021-09-20	2023-03-23	Regeneron Pharmaceuticals, Inc.	Methods of controlling antibody heterogeneity
MX2024004107A (es)	2021-10-07	2024-04-19	Regeneron Pharma	Sistemas y metodos para modelar y controlar el ph.
IL311248A (en)	2021-10-07	2024-05-01	Regeneron Pharma	PH meter calibration and repair
TW202330104A (zh)	2021-10-26	2023-08-01	美商再生元醫藥公司	用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
CN116284377A (zh) *	2021-12-21	2023-06-23	复旦大学	抗人血管生成素3纳米抗体及其应用
WO2023122656A1 (en) *	2021-12-22	2023-06-29	Regeneron Pharmaceuticals, Inc.	Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors
AR128824A1 (es)	2022-03-18	2024-06-19	Regeneron Pharma	Métodos de análisis y cuantificación de variantes polipeptídicas de carga
TWI833641B (zh) *	2022-05-02	2024-02-21	丹麥商諾佛儂迪克股份有限公司	適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體
CN117603361A (zh) *	2022-08-22	2024-02-27	复旦大学附属儿科医院	包含angptl3单抗的融合蛋白
CN116143919A (zh) *	2022-11-01	2023-05-23	中国药科大学	全人源抗人nt-angptl3抗体、其抗原结合片段及其应用
WO2024130165A1 (en) *	2022-12-16	2024-06-20	Regeneron Pharmaceuticals, Inc.	Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
US20240198253A1 (en)	2022-12-16	2024-06-20	Regeneron Pharmaceuticals, Inc.	Methods and systems for assessing chromatographic column integrity
US20240245779A1 (en)	2023-01-25	2024-07-25	Regeneron Pharmaceuticals, Inc.	Methods of modeling liquid protein composition stability
WO2024158961A1 (en)	2023-01-25	2024-08-02	Regeneron Pharmaceuticals, Inc.	Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240255519A1 (en)	2023-02-01	2024-08-01	Regeneron Pharmaceuticals, Inc.	Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en)	2023-02-22	2024-08-22	Regeneron Pharmaceuticals, Inc.	System suitability parameters and column aging
WO2024229136A1 (en)	2023-05-01	2024-11-07	Regeneron Pharmaceuticals, Inc.	Multidose antibody drug products using phenol or benzyl alcohol
CN117535353A (zh) *	2023-10-11	2024-02-09	首都医科大学附属北京潞河医院	一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020035058A1 (en)	1996-05-15	2002-03-21	The University Of Sheffield	Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en)	1997-09-19	2000-02-29	Genetech, Inc.	Tie ligand homologues
US7070959B1 (en)	1999-06-08	2006-07-04	Regeneron Pharmaceuticals, Inc.	Modified chimeric polypeptides with improved pharmacokinetic properties
ATE357216T1 (de)	2001-02-22	2007-04-15	Jagotec Ag	Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
JP5105696B2 (ja)	2001-11-16	2012-12-26	ジェネンテック，インコーポレイテッド	アンジオポエチン様タンパク質３Ａｎｇｐｔｌ３含有組成物とその使用方法
EP2322201A3 (en)	2002-10-29	2011-07-27	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US20040101920A1 (en)	2002-11-01	2004-05-27	Czeslaw Radziejewski	Modification assisted profiling (MAP) methodology
JP2005080508A (ja)	2003-09-04	2005-03-31	Sankyo Co Ltd	脂質代謝改善剤の試験方法
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
JP2008532516A (ja)	2005-03-11	2008-08-21	ジェネンテック・インコーポレーテッド	遺伝子破壊、組成物、およびそれに関連する方法
AU2006326417B2 (en)	2005-12-16	2012-05-24	Regeneron Pharmaceuticals, Inc.	Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
NZ587107A (en)	2006-06-02	2012-05-25	Regeneron Pharma	High affinity antibodies to human il-6 receptor
MEP11109A (en) *	2006-10-02	2011-12-20		High affinity human antibodies to human il-4 receptor
WO2008073300A2 (en)	2006-12-08	2008-06-19	Lexicon Pharmaceuticals, Inc.	Monoclonal antibodies against angptl3
NO347649B1 (no)	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US20130064834A1 (en)	2008-12-15	2013-03-14	Regeneron Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar)	2008-12-15	2020-08-27	Regeneron Pharma	أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2216016A1 (en)	2009-02-06	2010-08-11	LEK Pharmaceuticals d.d.	Process for the preparation of a pharmaceutical composition comprising ezetimibe
CN101852805B (zh)	2009-03-31	2015-04-01	浙江大学	Angptl3作为卵巢癌的诊断标记物的用途
SG177318A1 (en)	2009-07-14	2012-03-29	Scripps Research Inst	Mesenchymal stem cell differentiation
EP2521556B1 (en)	2010-01-08	2018-05-30	Ionis Pharmaceuticals, Inc.	Modulation of angiopoietin-like 3 expression
AR087329A1 (es)	2011-06-17	2014-03-19	Regeneron Pharma	Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
JP6110372B2 (ja) *	2011-06-21	2017-04-05	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及びその使用方法
US10111953B2 (en)	2013-05-30	2018-10-30	Regeneron Pharmaceuticals, Inc.	Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
HUE052243T2 (hu)	2013-12-24	2021-04-28	Ionis Pharmaceuticals Inc	Az angiopoietin-szerû 3 expressziójának modulációja
SI3137605T1 (sl)	2014-05-01	2021-02-26	Ionis Pharmaceuticals, Inc.	Sestavki in metode za modulacijo ekspresije angiopoetin 3-podobnega
KR20240017117A (ko)	2014-07-16	2024-02-06	사노피 바이오테크놀로지	이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
TW201713690A (zh)	2015-08-07	2017-04-16	再生元醫藥公司	抗ａｎｇｐｔｌ８抗體及其用途
MX2018009680A (es)	2016-02-17	2018-09-10	Regeneron Pharma	Metodos para tratar o prevenir la aterosclerosis administrando un inhibidor de angptl3.
EP3423157A1 (en)	2016-03-03	2019-01-09	Regeneron Pharmaceuticals, Inc.	Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
LT3439689T (lt)	2016-04-08	2021-11-10	Regeneron Pharmaceuticals, Inc.	Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi
KR20220148299A (ko)	2016-04-28	2022-11-04	리제너론 파아마슈티컬스, 인크.	가족성 고콜레스테롤혈증을 지닌 환자를 치료하는 방법
US20200369760A1 (en) *	2019-05-24	2020-11-26	Regeneron Pharmaceuticals, Inc.	Stabilized formulations containing anti-angptl3 antibodies

2012
- 2012-06-13 AR ARP120102099A patent/AR087329A1/es active IP Right Grant
- 2012-06-13 JO JOP/2012/0155A patent/JO3412B1/ar active
- 2012-06-14 UA UAA201314628A patent/UA114891C2/uk unknown
- 2012-06-14 LT LTEP12727767.1T patent/LT2721065T/lt unknown
- 2012-06-14 AU AU2012271663A patent/AU2012271663B2/en active Active
- 2012-06-14 SI SI201231444T patent/SI2721065T1/sl unknown
- 2012-06-14 MX MX2013014345A patent/MX337644B/es active IP Right Grant
- 2012-06-14 MY MYPI2013004223A patent/MY160516A/en unknown
- 2012-06-14 RU RU2013155906A patent/RU2620064C2/ru active
- 2012-06-14 TR TR2018/16591T patent/TR201816591T4/tr unknown
- 2012-06-14 US US13/517,662 patent/US9018356B2/en active Active
- 2012-06-14 EP EP18185031.4A patent/EP3418301A1/en not_active Withdrawn
- 2012-06-14 MX MX2015017575A patent/MX361859B/es unknown
- 2012-06-14 DK DK12727767.1T patent/DK2721065T3/en active
- 2012-06-14 PE PE2013002804A patent/PE20141166A1/es active IP Right Grant
- 2012-06-14 WO PCT/US2012/042338 patent/WO2012174178A1/en active Application Filing
- 2012-06-14 SM SM20180658T patent/SMT201800658T1/it unknown
- 2012-06-14 KR KR1020147000902A patent/KR102031007B1/ko active IP Right Grant
- 2012-06-14 ES ES12727767T patent/ES2699499T3/es active Active
- 2012-06-14 SG SG2013087432A patent/SG195165A1/en unknown
- 2012-06-14 PT PT12727767T patent/PT2721065T/pt unknown
- 2012-06-14 RS RS20181508A patent/RS58310B1/sr unknown
- 2012-06-14 CA CA2838867A patent/CA2838867C/en active Active
- 2012-06-14 EP EP12727767.1A patent/EP2721065B1/en active Active
- 2012-06-14 CN CN201280038908.0A patent/CN103732624B/zh active Active
- 2012-06-14 PL PL12727767T patent/PL2721065T3/pl unknown
- 2012-06-14 JP JP2014515976A patent/JP6400471B2/ja active Active
- 2012-06-15 UY UY0001039340A patent/UY39340A/es not_active Application Discontinuation
- 2012-06-15 TW TW101121453A patent/TWI644922B/zh active
- 2012-06-15 TW TW106123582A patent/TW201815822A/zh unknown
- 2012-06-15 TW TW107135714A patent/TW201920261A/zh unknown
- 2012-06-15 UY UY0001034137A patent/UY34137A/es not_active Application Discontinuation
2013
- 2013-11-25 IL IL229612A patent/IL229612B/en active IP Right Grant
- 2013-11-26 ZA ZA2013/08879A patent/ZA201308879B/en unknown
- 2013-11-26 CR CR20130621A patent/CR20130621A/es unknown
- 2013-12-06 NI NI201300136A patent/NI201300136A/es unknown
- 2013-12-11 CL CL2013003552A patent/CL2013003552A1/es unknown
- 2013-12-11 GT GT201300306A patent/GT201300306A/es unknown
- 2013-12-11 DO DO2013000299A patent/DOP2013000299A/es unknown
- 2013-12-13 CO CO13292222A patent/CO6821892A2/es unknown
- 2013-12-16 EC ECSP13013085 patent/ECSP13013085A/es unknown
- 2013-12-17 MA MA36579A patent/MA35190B1/fr unknown
2015
- 2015-03-24 US US14/667,121 patent/US9951127B2/en active Active
2018
- 2018-04-20 US US15/958,996 patent/US10358487B2/en active Active
- 2018-05-16 IL IL259436A patent/IL259436A/en active IP Right Grant
- 2018-07-06 JP JP2018128768A patent/JP2018166516A/ja active Pending
- 2018-12-11 CY CY181101324T patent/CY1120996T1/el unknown
- 2018-12-12 HR HRP20182098TT patent/HRP20182098T1/hr unknown
2019
- 2019-06-07 US US16/435,032 patent/US20190315851A1/en not_active Abandoned
2021
- 2021-09-01 NL NL301122C patent/NL301122I2/nl unknown
- 2021-09-06 LT LTPA2021009C patent/LTC2721065I2/lt unknown
- 2021-09-06 HU HUS2100034C patent/HUS2100034I1/hu unknown
- 2021-09-09 FI FIC20210028C patent/FIC20210028I1/fi unknown
- 2021-09-15 NO NO2021037C patent/NO2021037I1/no unknown
- 2021-09-23 LU LU00231C patent/LUC00231I2/fr unknown
- 2021-12-06 CY CY2021036C patent/CY2021036I2/el unknown
2022
- 2022-01-27 US US17/586,662 patent/US20220153825A1/en not_active Abandoned
- 2022-09-08 US US17/930,704 patent/US20220403016A1/en active Pending

Also Published As

Publication number	Publication date
AU2012271663B2 (en)	2017-04-20
FIC20210028I1 (fi)	2021-09-09
CA2838867A1 (en)	2012-12-20
ES2699499T3 (es)	2019-02-11
IL259436A (en)	2018-07-31
TW201313738A (zh)	2013-04-01
CR20130621A (es)	2014-02-12
CN103732624B (zh)	2016-08-17
UA114891C2 (uk)	2017-08-28
CY2021036I1 (el)	2022-03-24
PL2721065T3 (pl)	2019-02-28
ECSP13013085A (es)	2014-01-31
MY160516A (en)	2017-03-15
NL301122I1 (es)	2021-09-01
KR102031007B1 (ko)	2019-11-08
WO2012174178A1 (en)	2012-12-20
KR20140037218A (ko)	2014-03-26
US9951127B2 (en)	2018-04-24
LTPA2021009I1 (es)	2021-09-27
NL301122I2 (nl)	2021-12-30
US20190315851A1 (en)	2019-10-17
MA35190B1 (fr)	2014-06-02
RS58310B1 (sr)	2019-03-29
US20190092845A1 (en)	2019-03-28
NI201300136A (es)	2014-05-15
US20130171149A1 (en)	2013-07-04
US20220403016A1 (en)	2022-12-22
ZA201308879B (en)	2014-07-30
HRP20182098T1 (hr)	2019-02-08
LUC00231I2 (es)	2025-02-03
SG195165A1 (en)	2013-12-30
JP2014523739A (ja)	2014-09-18
EP2721065A1 (en)	2014-04-23
LT2721065T (lt)	2018-12-10
SMT201800658T1 (it)	2019-01-11
JO3412B1 (ar)	2019-10-20
JP6400471B2 (ja)	2018-10-03
US20220153825A1 (en)	2022-05-19
UY34137A (es)	2013-01-03
CY2021036I2 (el)	2022-05-27
RU2013155906A (ru)	2015-07-27
TW201920261A (zh)	2019-06-01
CY1120996T1 (el)	2019-12-11
US20150197564A1 (en)	2015-07-16
EP2721065B1 (en)	2018-09-12
RU2620064C2 (ru)	2017-05-22
IL229612B (en)	2019-06-30
NZ619092A (en)	2016-03-31
CN103732624A (zh)	2014-04-16
HUS2100034I1 (hu)	2021-10-28
AR087329A1 (es)	2014-03-19
US10358487B2 (en)	2019-07-23
CL2013003552A1 (es)	2014-07-25
SI2721065T1 (sl)	2018-12-31
IL229612A0 (en)	2014-01-30
TW201815822A (zh)	2018-05-01
US9018356B2 (en)	2015-04-28
NO2021037I1 (no)	2021-09-15
MX361859B (es)	2018-12-18
DK2721065T3 (en)	2018-12-03
LTC2721065I2 (es)	2022-10-25
TR201816591T4 (tr)	2018-11-21
JP2018166516A (ja)	2018-11-01
CA2838867C (en)	2020-07-14
PE20141166A1 (es)	2014-09-16
GT201300306A (es)	2015-03-09
MX2013014345A (es)	2014-01-31
DOP2013000299A (es)	2014-04-15
PT2721065T (pt)	2018-12-06
UY39340A (es)	2021-08-31
EP3418301A1 (en)	2018-12-26
AU2012271663A1 (en)	2014-01-16
TWI644922B (zh)	2018-12-21
MX337644B (es)	2016-03-14

Publication	Publication Date	Title
CY2024011I2 (el)	2024-12-13	Αντισωματα anti-fcrn
HUS2300021I1 (hu)	2023-07-28	Anti-IL-36R antitestek
CO6821892A2 (es)	2013-12-31	Anticuerpos anti-angptl3 y usos de los mismos
CO6940383A2 (es)	2014-05-09	Anticuerpos anti-erbb3 y usos de los mismos
CO7020859A2 (es)	2014-08-11	Anticuerpos anti-cd134 (ox40) y usos de los mismos
CO6980627A2 (es)	2014-06-27	Anticuerpos anti-pfh-tau y sus usos
CO6940376A2 (es)	2014-05-09	Anticuerpos anti-psgl-1 y usos de los mismos
CL2016000251A1 (es)	2017-07-14	Anticuerpos anti-activina y usos de los mismos
CO7030961A2 (es)	2014-08-21	Benzotienilo-pirrolotriazinas disustituidas y sus usos
CO6910164A2 (es)	2014-03-31	Anticuerpos a pcsk9 y usos de los mismos
BR112014012137A2 (pt)	2017-05-30	anticorpos anti-fgfr2 e suas utilizações
DK2934584T3 (da)	2020-05-18	Anti-gdf15-antistoffer
CL2014002086A1 (es)	2015-02-27	Anticuerpos cd47 y métodos de uso los mismos
SMT202000512T1 (it)	2021-01-05	Anticorpi anti-tau umani
CO7010785A2 (es)	2014-07-31	Anticuerpos específicos para trop-2 y sus usos
CO7061078A2 (es)	2014-09-19	Compuestos de enediino, conjugados de los mismos y sus usos y metodos
DK3275892T3 (da)	2020-04-06	Præfusions-rsv-f-antigener
DK3381943T3 (da)	2022-05-16	Anti-kit-antistoffer og anvendelser deraf
EP2714735A4 (en)	2014-12-31	SPECIFIC ANTIBODIES OF TGF BETA
CO6870031A2 (es)	2014-02-20	Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
CO6990717A2 (es)	2014-07-10	Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
DK2668210T3 (da)	2020-08-24	Anti-kit antistoffer og anvendelser deraf
CO7000747A2 (es)	2014-07-21	Anticuerpos anti-lrp5 y métodos de uso
BR112014025037A2 (pt)	2018-07-31	anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
DK3453723T3 (da)	2021-09-13	Anti-ASIC1-antistoffer og anvendelser deraf